AVEO AVEO Pharmaceuticals Inc

Neurocrine Biosciences came within a penny of Tuesday’s all-time high of $125.99 before pulling back. The company’s treatment for a disorder called tardive dyskinesia, which accounts for nearly all the company’s revenue, came in higher than expected.  The stock is up 15.33% in the past month. In the company’s Q3 earnings report earlier this month, […]
https://www.valuewalk.com/is-mid-cap-neurocrine-biosciences-a-buy-after-blowout-q3-report/